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Stress and glucocorticoid hormones regulate hippocampal neuro-
genesis, but the molecular mechanisms mediating these effects are
poorly understood. Here we identify the glucocorticoid receptor (GR)
target gene, serum- and glucocorticoid-inducible kinase 1 (SGK1), as
onesuchmechanism.Usingahumanhippocampalprogenitor cell line,
we found that a small molecule inhibitor for SGK1, GSK650394,
counteracted the cortisol-induced reduction in neurogenesis. More-
over, gene expression and pathway analysis showed that inhibition of
the neurogenic Hedgehog pathway by cortisol was SGK1-dependent.
SGK1alsopotentiatedandmaintainedGRactivation in thepresenceof
cortisol, and even after cortisol withdrawal, by increasing GR phos-
phorylation and GR nuclear translocation. Experiments combining
the inhibitor for SGK1, GSK650394, with the GR antagonist, RU486,
demonstrated that SGK1 was involved in the cortisol-induced re-
duction in progenitor proliferation both downstream of GR, by
regulating relevant target genes, andupstreamofGR, by increasing
GR function. Corroborating the relevance of these ﬁndings in clinical
and rodent settings, we also observed a signiﬁcant increase of SGK1
mRNA in peripheral blood of drug-free depressed patients, as well as
in the hippocampus of rats subjected to either unpredictable chronic
mild stress or prenatal stress.Ourﬁndings identify SGK1as amediator
for the effects of cortisol on neurogenesis and GR function, with par-
ticular relevance to stress and depression.
antidepressants | hypothalamus–pituitary–adrenal axis | stem cells |
neuroplasticity
Glucocorticoid hormones are consistently increased in severelydepressed patients and in rodent stress models (1). A large
body of evidence has demonstrated that chronically high con-
centrations of glucocorticoids impair hippocampal neurogenesis,
that is, the development of new neurons from stem cells in the
dentate gyrus, by activating the glucocorticoid receptor (GR) (1–
6). However, the mechanisms by which GR activation reduces
neurogenesis are not fully understood. Here we explore the role
of the GR target gene, serum- and glucocorticoid-regulated ki-
nase 1 (SGK1), in these effects.
SGK1 is a serine/threonine kinase implicated in the cellular
stress response and neuronal function (7). We and others have
previously shown that glucocorticoids increase SGK1 expression
in human neural stem cells and in rodent neurons (3, 8). Impor-
tantly, SGK1 mediates some glucocorticoid effects on brain func-
tion; for example, acute stress enhances neuronal excitability and
working memory in the rodent prefrontal cortex via glucocorticoid-
induced activation of SGK1 (9), and chronic stress causes mor-
phological oligodendrocyte abnormalities by up-regulating SGK1
in the murine corpus callosum (10). These data suggest that SGK1
may be a downstream mediator of glucocorticoid effects on the
brain. However, recent evidence has also suggested that enhanced
SGK1 expression is associated with greater GR-mediated gene
expression in response to glucocorticoids (11). Therefore, another,
nonmutually exclusive possibility is that SGK1 also directly en-
hances GR function and potentiates glucocorticoid effects. Here
we examined both these possibilities.
We have previously used a human hippocampal progenitor cell
line to examine the effects of glucocorticoids and antidepressants
on neurogenesis (3, 6, 12), and we have shown that inhibition of
Hedgehog signaling critically contributes to the reduction in neuronal
differentiation upon treatment with the human glucocorticoid hor-
mone, cortisol (6). Here we investigate the role of SGK1 in these
effects of cortisol in vitro. Moreover, we analyze SGK1 gene ex-
pression in the peripheral blood of drug-free depressed patients, and
in the hippocampus of rats exposed to unpredictable chronic mild
stress (UCMS) or prenatal stress (PNS), two in vivo stress models
known to precipitate depressive behavior and to decrease hippo-
campal neurogenesis (13–15). Our ﬁndings identify SGK1 as a key
enzyme involved in the downstream mechanisms by which gluco-
corticoids reduce neurogenesis and in the upstream potentiation and
maintenance of GR function, even after glucocorticoid withdrawal.
Results
SGK1 Mediates the Cortisol-Induced Decrease in Neurogenesis. We
have previously reported that GR activation increases SGK1 ex-
pression, and that GR-mediated concentrations of cortisol (CORT)
decrease proliferation and neuronal differentiation of human hip-
pocampal progenitor cells (3, 6). In particular, we have shown that
the concentration of 100 μM CORT exerts consistent GR-medi-
ated effects on cell proliferation and neuronal differentiation, and
induces GR transactivation without saturating the receptor re-
sponse (6). This concentration was thus used for the present study.
Here we used the small molecule inhibitor for SGK1, GSK650394
(16), to test whether SGK1 is mechanistically involved in the effects
of CORT on neurogenesis. As hypothesized, GSK650394 (at 10 nM,
50 nM, and 100 nM) dose-dependently counteracted the CORT-
induced reduction in BrdU-positive, proliferating progenitor
cells (one-way ANOVA, P = 0.01, F1,4 = 4.17; Fig. 1 A and B).
Author contributions: C.A., S.T., J.P., R.U., M.A.R., and C.M.P. designed research; C.A., A.C.,
K.M., P.A.Z., M.H., R.M., A.L., and F.C. performed research; M.G. contributed new re-
agents/analytic tools; C.A., A.C., P.A.Z., and K.T. analyzed data; and C.A. and C.M.P. wrote
the paper.
Conﬂict of interest statement: J.P. acted as a consultant and received payment from
ReNeuron Group within the last 2 y. C.M.P. has received fees as a speaker or as a mem-
ber of advisory board, as well as research funding, from pharmaceutical companies
that commercialize or are developing antidepressants in the last 3 y, such as Lilly,
Servier, and Janssen. M.A.R. has received compensation as speaker/consultant for As-
traZeneca, Bristol-Myers Squibb, Eli Lilly, Servier, and Takeda. P.A.Z. has received
speaker fees from Servier.
This article is a PNAS Direct Submission.
Freely available online through the PNAS open access option.
1To whom correspondence should be addressed. E-mail: Christoph.Anacker@kcl.ac.uk.
This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.
1073/pnas.1300886110/-/DCSupplemental.
8708–8713 | PNAS | May 21, 2013 | vol. 110 | no. 21 www.pnas.org/cgi/doi/10.1073/pnas.1300886110
GSK650394 alone did not exert any effects on proliferation at
these concentrations (one-way ANOVA, P = 0.84, F1,3 = 0.178;
Fig. 1C), indicating that SGK1 indeed mediates the effect of
CORT, but does not eliciting any effect by itself.
We also examined differentiation into Dcx-positive neuroblasts
and into microtubule-associated protein 2 (MAP2)-positive neurons
(Fig. 1D). In line with our ﬁndings on proliferation, the dose of
GSK650394 that most effectively counteracted the effects of CORT
on proliferation (100 nM, as shown in Fig. 1B) also counteracted
the CORT-induced reduction in Dcx-positive (P = 0.003; Fig. 1E)
and in MAP2-positive cells (P = 0.03; Fig. 1F). Taken together,
these data demonstrate that CORT decreases hippocampal
progenitor cell proliferation and neuronal differentiation via
an SGK1-dependent mechanism.
Cortisol Increases SGK1 Expression. We then further characterized
the time course of CORT-induced SGK1 expression. SGK1 mRNA
was marginally elevated after 1 h (1.3 ± 0.2 fold, P = 0.11), but
signiﬁcantly increased after 3 h (1.7 ± 0.08 fold, P = 0.01), 12 h
(1.7 ± 0.03, P = 0.002) and 72 h (1.7 ± 0.09 fold, P = 0.02) of
treatment (Fig. 2A). Moreover, the GR-antagonist, RU486
(50 nM), abolished the CORT-induced increase in SGK1 mRNA
(Fig. S1A), conﬁrming that this effect is GR-dependent. In line
with our ﬁndings on the mRNA level, no changes in SGK1 protein
were observed after 1 h of CORT treatment (1.4 ± 0.5 fold, P =
0.5), whereas treatment for 12 h signiﬁcantly increased SGK1
protein levels (by 4.4 ± 1.1 fold, P = 0.02) (Fig. S1B). Finally,
after 12 h of treatment, SGK1 expression was signiﬁcantly in-
creased only by high concentrations of CORT (100 μM), but not
by lower concentrations (1–100 nM) (Fig. 2B). This result is in
line with our previous data, showing that 100 μM CORT pre-
dominantly affects the GR, whereas 1–100 nM CORT pre-
dominantly affects the MR in the same cells (6).
SGK1 Is Involved in Cortisol-Induced Changes in Molecular Signaling
Pathways. We have previously shown that cortisol decreases neuro-
nal differentiation by inhibiting Hedgehog signaling (6). Here we
conducted Affymetrix gene expression microarray and pathway
analysis on mRNA samples of cells treated with CORT (100 μM)
and GSK650394 (100 nM). Using this approach, we conﬁrm and
extend our previous ﬁndings, by showing that CORT signiﬁcantly
decreasesHedgehog signaling (vehicle vs. 100 μMCORT; P= 0.04,
n = 5) and that this effect is counteracted by GSK650394 (vehicle vs.
100 μM CORT + 100 nM GSK650394; P = 0.22, n = 5). Ac-
cordingly, quantitative real-time PCR (qRT-PCR) analysis con-
ﬁrmed that the CORT-induced decrease in expression of the key
Hedgehog genes, glioma-associated oncogene (Gli) and Smoothened
(Smo)was counteracted byGSK650394 (one-way ANOVA forGli:
P = 0.005, F1,3 = 6.63, Fig. 2C; for Smo: P = 0.006, F1,3 = 6.9,
Fig. 2D).
SGK1 Mediates the Cortisol-Induced Increase in GR Phosphorylation.
Next, we wanted to test whether SGK1 may also act as an “up-
stream” regulator of the GR. Therefore, we investigated a criti-
cal component of GR function: phosphorylation at the serine
residues S203, S211, and S226. CORT treatment for 12 h induced
phosphorylation at the phospho-sites S203 (by 1.5 ± 0.1 fold, P =
0.007), S211 (by 2.1 ± 0.4 fold, P = 0.01), and S226 (by 1.5 ± 0.2
fold, P = 0.03). Interestingly, the SGK1-inhibitor, GSK650394 (100
nM), blocked the CORT-induced phosphorylation at S203 (P =
0.01) and S211 (P = 0.04), but not at S226 (P = 0.4) (Fig. 3 A–C).
Importantly, SGK1 was involved in GR phosphorylation only
when SGK1 expression was increased (that is, after 12 h of
cortisol treatment), but not at low, basal levels. In fact, after 1 h
of CORT treatment, when SGK1 levels are not yet elevated
(as shown in Fig. 2A and Fig. S1B), GR phosphorylation was
already increased at S203 (by 2.5 ± 0.5-fold, P = 0.04), S211 (by
6.9 ± 2.4-fold, P = 0.04), and S226 (by 2.8 ± 0.9-fold, P = 0.07),
but these effects were not counteracted by GSK650394 (Fig. S2
A–C). Kinases involved in this early, SGK1-independent GR
phosphorylation are presented in SI Results and Fig. S3.
SGK1 Mediates Cortisol-Induced GR Nuclear Translocation. Having
demonstrated that SGK1 mediates the cortisol-induced increase
in GR phosphorylation at the S203 and S211 phospho-sites, which
enhance GR nuclear translocation, but not at the S226 site, which
inhibits nuclear translocation, we then directly assessed SGK1-
dependent changes in GR nuclear translocation upon cortisol
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Fig. 1. CORT (100 μM) decreases neurogenesis via an SGK1-dependent effect.
(A) BrdU immunocytochemistry (ICC) was used to assess proliferation. (B) The
SGK1 inhibitor, GSK650394 (10 nM, 50 nM, 100 nM) dose-dependently coun-
teracted the CORT-induced reduction in proliferation (n = 4). (C) GSK650394
alone did not change proliferation (n = 4). (D) ICC for doublecortin (Dcx) and
microtubule-associated protein 2 (MAP2) was used to assess neuronal differ-
entiation. (E and F) GSK650394 (100 nM) counteracted the CORT-induced
decrease in Dcx-positive neuroblasts (n = 3; E) and in MAP2-positive neurons
(n = 3; F). Data are mean ± SEM *P < 0.05, **P < 0.01; ***P < 0.001.
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treatment. As expected, after 12 h of treatment, CORT induced
GR nuclear translocation as indicated by a 3.5-fold increase in
GR nuclear protein (P = 0.008; Fig. 4 A and B). Cotreatment
with GSK650394 counteracted this effect (P = 0.02; Fig. 4B),
demonstrating that CORT induces GR translocation via an
SGK1-dependent mechanism. In contrast, cytoplasmic levels of
GR were decreased upon CORT treatment (by 44%, P = 0.02),
but this decrease was not counteracted by GSK650394 (Fig.
4C), suggesting that this effect may rather reﬂect an SGK1-
independent decrease in overall GR expression. This ﬁnding
was conﬁrmed by a separate set of experiments in which we
found that CORT decreases GR protein expression in whole cell
lysates (by 20%, P = 0.04), and that this effect was also not
counteracted by GSK650394 (Fig. S4). Taken together, these
data demonstrate that SGK1 is also involved in regulating GR
activation and translocation during glucocorticoid exposure.
SGK1 Maintains GR Activation in the Absence of Cortisol. Having
shown that CORT increases SGK1 levels, and that these increased
SGK1 levels mediate the CORT-induced GR phosphorylation
and nuclear translocation, we then tested the hypothesis that
SGK1 may maintain GR activation even after CORT has been
removed. Therefore, we treated cells with CORT for 3 h, a time
long enough to signiﬁcantly induce SGK1 mRNA expression (as
shown in Fig. 2A). We then extensively washed cells in CORT-
free media and investigated GR nuclear translocation after a total
incubation time of 12 h, that is, after further 9 h of incubation in
the absence of CORT (Fig. 4D). At 12 h, even though CORT
had not been present for the last 9 h, SGK1 protein expression
was still increased (by ∼2-fold, P = 0.04) and the GR was still
translocated to the nucleus (by ∼4.5-fold, P = 0.04; Fig. 4E).
Indeed, this persistent GR translocation in the absence of CORT
was maintained by SGK1, because it was counteracted when
SGK1 was blocked during the 9-h period after the end of the
initial 3-h CORT treatment (P = 0.02; Fig. 4E, third column).
Again, and in line with our data on continuous CORT treatment
for 12 h, cytoplasmic GR was decreased even after CORT removal
(by 17%, P = 0.02), and this effect was not counteracted by the
SGK1 inhibitor (Fig. 4F), likely reﬂecting an SGK1-independent
reduction in overall GR expression, as discussed above.
SGK1 Mediates the Decrease In Progenitor Proliferation After Cortisol
Removal. In light of our ﬁnding that SGK1 maintains GR trans-
location even after CORT removal, we next tested whether
progenitor cell proliferation was also decreased under these
conditions. We thus treated cells with CORT for 3 h, washed
them extensively in CORT-free media, and then investigated
proliferation 69 h later (that is, after a total incubation time of
72 h). Even though CORT was only present for the ﬁrst 3 h of
incubation, it was sufﬁcient to reduce proliferation to levels com-
parable to those after continuous 72-h treatment (∼11%, P =
0.0009; Fig. 5A, ﬁrst column). We then incubated cells with the
SGK1 inhibitor, GSK650394, during the 69-h period after the
initial 3-h CORT stimulus, that is, in the absence of any CORT.
As hypothesized, this treatment completely abolished the CORT-
induced reduction in proliferation (P = 0.0012; Fig. 5A, second
column). These data thus suggest that the CORT-induced SGK1
expression maintains GR activation even after CORT removal,
1h 3h 12h 72h
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Fig. 2. CORT increases SGK1 expression and inhibits Hedge-
hog signaling. (A) CORT (100 μM) increases SGK1 mRNA ex-
pression after 3, 12, and 72 h (n = 3). (B) CORT (1 nM to 100 μM
for 12 h) dose-dependently increases SGK1 mRNA expression
(n = 6). (C and D) GSK650394 (100 nM) counteracts the CORT
(100 μM)-induced decrease of the Hedgehog pathway genes
Gli (n = 6; C) and SMO (n = 6; D). Data are mean ± SEM *P <
0.05, **P < 0.01; ***P < 0.001.
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phorylation. After 12 h, CORT (100 μM) increases GR
phosphorylation at S203 (n = 6; A), S211 (n = 6; B),
and S226 (n = 6; C). GSK650394 (100 nM) counter-
acted the increase in S203 and S211 phosphoryla-
tion. Data are mean ± SEM *P < 0.05, **P < 0.01.
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and that this SGK1-dependent GR activation (in the absence of
CORT) is functionally relevant for prolonging the effects of CORT
on hippocampal progenitor proliferation.
SGK1 Effects on Proliferation Occur both Upstream and Downstream
of the GR. In the above-described experiments, we have demon-
strated a role for SGK1 in mediating cortisol effects on human
hippocampal progenitor cells. We now wanted to clarify whether
these effects of SGK1 were predominantly downstream or up-
stream of GR activation. Therefore, we treated cells as above
(CORT for only 3 h, then investigated proliferation 69 h later),
but in the presence of the GR antagonist, RU486 (50 nM),
during the 69-h period after CORT treatment. We had pre-
viously demonstrated that coincubation with RU486 blocks the
CORT-induced reduction in proliferation after 72 h (6). In these
novel experimental conditions, if the effects of the 3-h CORT
treatment on proliferation were blocked by RU486 (during the
69 h after the initial CORT stimulus), it would indicate that the
decrease in proliferation was dependent on the ability of SGK1
to maintain GR activation; in contrast, if the effects of the 3-h
CORT treatment were not blocked by RU486 (during the 69 h
after CORT), it would indicate that increased levels of SGK1
were sufﬁcient to exert all downstream effects leading to decreased
proliferation. Interestingly, treatment with RU486 only partially
counteracted the reduction in proliferation (by ∼60%, P = 0.04;
Fig. 5A, third column). These data thus suggest that SGK1 medi-
ates the CORT-induced reduction in hippocampal progenitor
proliferation by acting both upstream of GR, by enhancing GR
function, as well as downstream of GR, by regulating neuro-
genesis-relevant molecular targets (Fig. 5B).
Increased SGK1 mRNA Expression in Depressed Patients. To corrob-
orate the clinical relevance of our cellular and molecular ﬁndings,
we measured SGK1 mRNA expression in peripheral blood of
patients with major depression, a condition in which both hyper-
cortisolemia and reduced neurogenesis are considered relevant
pathophysiological mechanisms. We have previously described
candidate gene expression proﬁles associated with GR function
and neuroplasticity in the Genome-based Therapeutic Drugs
for Depression (GENDEP) study (17). Here we analyzed SGK1
expression in a subpopulation of this cohort. All patients (n = 25)
were drug-free for at least 2 wk before assessment, and 18 of these
25 patients were drug naïve. Controls (n = 14) had no present or
past psychiatric disorder and did not take any hormonal treatment.
There were no signiﬁcant differences in age and sex between
patients and controls (P = 0.97 for age, and P = 0.74 for sex).
The full patients’ clinical characteristics and inclusion criteria are
described in the SI Materials and Methods.
In line with our data on human hippocampal progenitor cells,
we found that depressed patients had signiﬁcantly higher SGK1
mRNA levels (by ∼2.5-fold; controls: 1.26 ± 0.16, patients: 3.11 ±
0.24, P < 0.0001, Fig. 6A). Even though our sample included
more male than female patients (n = 15 males, n = 10 females),
there was no effect of sex on SGK1mRNA expression in controls
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SEM *P < 0.05, **P < 0.01; ***P < 0.001. (B) Diagram depicting the proposed
model of SGK1-dependent regulation of neurogenesis and GR function.
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(female controls: 1.27 ± 0.3, n = 7, male controls: 1.24 ± 0.13,
n = 7; P = 0.9) or depressed patients (female depressed: 3.14 ± 0.3,
n = 10, male depressed: 3.09 ± 0.3, n = 15; P = 0.9). Moreover,
we correlated SGK1 expression with the expression of GR-relevant
genes that we had previously analyzed in the same individuals (17).
Consistent with our in vitro data showing decreased GR in the
presence of increased SGK1 expression, SGK1 mRNA levels cor-
related negatively with GR levels in our clinical sample (r = −0.32,
P = 0.046). Moreover, SGK1 correlated positively with mRNA
levels of the GR-target gene, FK506 binding protein 5 (FKBP5) (r =
0.45, P = 0.004), and negatively with genes involved in neuro-
plasticity [brain-derived neurotrophic factor (BDNF): r = −0.32, P =
0.05; VGF: r = −0.33, P = 0.037; p11: r = −0.43, P = 0.007].
Increased Hippocampal SGK1 Expression in Rodent Stress Models.
Finally, we analyzed SGK1 mRNA expression in the hippocam-
pus of adult rats exposed to two well established rodent models
of depression, characterized by both increased corticosterone
levels and reduced neurogenesis (13–15): unpredictable chronic
mild stress (UCMS) and prenatal stress (PNS). UCMS has been
shown to reduce hippocampal neurogenesis in the ventral and in
the dorsal hippocampus (18). Accordingly, in our experiments,
UCMS signiﬁcantly increased SGK1 expression both in the ventral
hippocampus (by ∼1.4-fold, P < 0.001, n = 8) and in the dorsal
hippocampus (by ∼1.2-fold, P < 0.01, n = 8) (Fig. 6B). In addition,
we had previously shown that PNS causes increased blood cor-
ticosterone levels and molecular signaling changes in the rat
hippocampus, including a reduction in Hedgehog signaling (6).
For the current study, we analyzed SGK1 mRNA expression in
the whole hippocampus of the same rats and found an increase
of ∼1.4-fold (P = 0.02, n = 5, Fig. S5). These data in rodent
stress models thus further support an important role for SGK1
in stress and glucocorticoid effects on the hippocampus.
Discussion
Here we demonstrate that the GR target gene, SGK1, mediates
the cortisol-induced decrease in proliferation and neuronal dif-
ferentiation of human hippocampal progenitor cells, by acting
both downstream of GR activation (via SGK1-dependent inhi-
bition of the Hedgehog pathway) and upstream of GR activation
(via SGK1-dependent GR phosphorylation and nuclear trans-
location). Additionally, we ﬁnd that SGK1 mRNA is increased in
the peripheral blood of drug-free depressed patients and in the
hippocampus of rats after unpredictable chronic mild stress and
prenatal stress. Our ﬁndings identify SGK1 as a mechanism for
mediating glucocorticoid effects on neurogenesis and for enhancing
GR activation, which may be of particular relevance for stress-
induced mental disorders, such as depression.
Although SGK1 was initially described for its role in regulating
sodium transport in renal collecting duct cells (19), recent studies
have provided evidence for a novel role of this kinase in stress and
glucocorticoid actions on the brain (9, 10). Our study extends these
previous ﬁndings by showing that SGK1 also mediates the inhibitory
effects of cortisol on proliferation and neuronal differentiation of
human hippocampal progenitor cells. Moreover, we ﬁnd that in-
hibition of Hedgehog signaling may be one of the molecular mech-
anisms resulting from the increased SGK1 expression by cortisol.
Importantly, we demonstrate that SGK1 is not only a mecha-
nism “downstream” of GR activation, but is in fact also involved
in regulating GR function. Speciﬁcally, the GR-mediated increase
in SGK1 expression upon cortisol treatment further enhances GR
phosphorylation at the serine residues S203 and S211, which are
phosphorylation sites known to facilitate nuclear translocation of
the receptor (20, 21). Accordingly, SGK1 enhances and maintains
GR nuclear translocation even after cortisol withdrawal. This
sustained SGK1-mediated GR activation in the absence of cor-
tisol has functional consequences and results in a reduction in
progenitor proliferation that is abolished by inhibiting SGK1 even
after cortisol has been removed. This interpretation is consistent
with studies showing that a single-nucleotide polymorphism in the
SGK1 promoter region, with a putative effect on increasing SGK1
expression upon glucocorticoid treatment, enhances glucocorticoid-
mediated gene transcription (11). Therefore, we propose that
GR-dependent SGK1 up-regulation may be a mechanism for
maintaining and prolonging GR activation after exposure to
increased glucocorticoid levels, such as during stress, and even
after glucocorticoid levels have normalized.
Our human in vitro data appear to be relevant also in vivo both
in rodents and in humans, as we have identiﬁed increased SGK1
mRNA expression in the hippocampus of rats exposed to two dif-
ferent types of stress, and in the blood of drug-free depressed
patients. Speciﬁcally, UCMS increased SGK1 expression both in the
ventral and in the dorsal hippocampus, which is in line with studies
showing that UCMS also decreases neurogenesis in both of these
regions (18). Considering that the ventral hippocampus has been
implicated in mood, whereas the dorsal hippocampus has been
implicated predominantly in cognition (22), the role of SGK1 in the
effects of glucocorticoids on neurogenesis and behavior in rodent
stress models will be an interesting line of future investigation.
The negative correlation between SGK1 and levels of three
genes involved in neuroplasticity in our clinical sample (BDNF,
VGF, and p11), may offer an indication that this mechanism may
also potentially be involved in regulating neurogenesis in de-
pression. However, although adult hippocampal neurogenesis has
repeatedly been implicated in stress-induced depressive symptoms
and antidepressant treatment response in rodents (23, 24), the
functional role of neurogenesis in humans remains elusive. Indeed,
compared with rodents, relatively few neurons are being added to
the human brain (25), and human postmortem brain studies have
delivered conﬂicting results with regards to changes in hippocam-
pal cell proliferation in depression and upon antidepressant
treatment (26–28). It is also important to mention that one pre-
vious report has examined SGK1 mRNA expression in depressed
patients, and found no difference compared with controls (29);
this may likely be due to the fact that in their study, 29 of the 40
patients were on antidepressants, and not drug-free as in our study.
Interestingly, under certain conditions stress may also lead to an
increase in neurogenesis in the presence of elevated glucocorticoids,
particularly when the stress has hedonic value, for example, during
mating (30), environmental enrichment (31) or physical exercise (32).
Indeed, some studies have suggested that concomitant regulation of
protective factors, such as oxytocin, may contribute to the neuro-
genesis increase in these situations (33). Whether SGK1 also con-
tributes to such “protective” effects of glucocorticoids remains to
be elucidated.
Some limitations of our study need to be considered: First, al-
though we have determined that the cortisol effects in our in vitro
experiments are inﬂuenced by albumin in the cell culture media (SI
Results and Fig S6), it is difﬁcult to estimate how the cortisol con-
centrations in our cell culture experiments compare with physio-
logical cortisol concentrations in the human hippocampus in vivo.
Second, the sample size of our clinical population is small and the
changes in SGK1 mRNA expression should thus be replicated in
a second cohort of drug-free depressed patients. Although all de-
pressed patients included in this study were drug-free for at least 2
wk at the time of assessment, and ∼70% were in fact drug-naïve,
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Fig. 6. SGK1 mRNA expression is increased in drug-free depressed patients
(ctrls, n = 14; patients, n = 25) (A) and the ventral and dorsal hippocampus of
rats upon unpredictable chronic mild stress (UCMS, n = 8; B). Data are mean ±
SEM; **P < 0.01; ***P < 0.001.
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we cannot fully exclude an inﬂuence of previous antidepressant
medication on SGK1 expression in some of our patients.
In conclusion, and in light of recent ﬁndings demonstrating
that neurogenesis is important for antidepressant treatment
response (4, 23), depression pathogenesis (24), and HPA axis
regulation (24, 34), we propose that SGK1 may represent an
antidepressant treatment strategy to counteract stress-induced
impairments in neurogenesis and associated biological abnor-
malities in depression.
Materials and Methods
The complete description can be found in SI Materials and Methods.
Cell Culture and Neurogenesis Assay. The immortalized, multipotent human
fetal hippocampal progenitor cell line, HPC03A/07 (propriety of ReNeuron),
was used for all cellular and molecular analyses (3, 6, 12, 35). Details of this
cell line, the differentiation protocol and immunocytochemistry can be found
in SI Materials and Methods.
Western Blot Analysis. Protein lysates were obtained using whole-cell protein
extraction buffer [20 mM Tris·HCl/150 mM NaCl/1 mM EDTA/1 mM EGTA/1%
(vol/vol) Triton X-100/2 nM calyculin A/1×protease and phosphatase inhib-
itors (Pierce, Thermo Fisher Scientiﬁc)] and commercially available Nuclear
Extraction kits (Active Motif). Samples were processed using NuPAGE system
(Invitrogen) and analyzed by Western Blot.
Gene Expression Analysis. RNA was isolated from human cells and rat tissue
using RNeasy mini kit (Qiagen). Human bloodwas collected in PaxGene Tubes
(Qiagen) and RNA was isolated using the PAXGene Blood RNA kit (Qiagen).
RNAwas reverse-transcribedwith SuperScript III (Invitrogen) before quantitative
real-time PCR (qRT-PCR).Microarraywas performed using HumanGenomeU219
Array on the Affymetrix GeneAtlas platform. Partek software (Ariadne) was
used for quality control and to identify signaling pathways.
Recruitment and Assessment of Depressed Patients.We selected 25 depressed
patients (10 females, 15 males) from the Genome-based Therapeutic Drugs
for Depression (GENDEP) study who were drug-naïve or had been drug-free
for at least 2 wk before assessment (17, 36). Controls (7 females, 7 males) were
recruited in London through local advertisement and volunteer databases, as
part of the GENDEP study. The study was approved by the Institute of Psy-
chiatry Research Ethical Committee (#292/03) and by the ethics boards in all
participating centers. All participants provided written consent. Subject char-
acteristics and exclusion criteria are detailed in the SI Materials and Methods.
Rodent Stress Procedures. For UCMS, male Sprague–Dawley rats were ex-
posed to a variable sequence of mild to moderate, unpredictable stressors
once or twice daily for a total duration of 6 wk. For PNS, pregnant dams
were restraint in Plexiglas cylinders under bright light during the last week
of gestation and male offspring were assessed at postnatal day 62. All
procedures were in accordance with the European Economic Communities
Council Directive 86/609 1987, Decreto Legislativo 116/92, and the National
Institutes of Health Guide for the Care and Use of Laboratory Animals and
were approved by the University of Milan Animals Research Committee.
Statistical Analysis. Multiple comparisons were conducted using one-way
ANOVA with Newman–Keuls post hoc test. Means of two treatment groups
were analyzed using Student t test or Mann–Whitney test. Pathway regu-
lation was assessed using Robust MultiChip Average ANOVA and Mann–
Whitney U test. Pearson correlation was used to correlate gene expression
changes. Data are presented as mean ± SEM.
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